



III International Conference on

# VACCINES RESEARCH & DEVELOPMENT

Vaccines R&D-2017

November 13-15, 2017 | Washington, D.C., USA

## TENTATIVE PROGRAM

### Conference Topics

**Cancer Vaccines**  
**Veterinary Vaccines**  
**Infectious & Non-Infectious Diseases**  
**Bio-defense Vaccines**  
**Vaccines Against Respiratory Pathogens**  
**Influenza Vaccines/Virus**  
**Passive Vaccines**  
**New Vaccine Development**  
**Therapeutic Vaccination**  
**Clinical Trials**  
**DNA Vaccines**  
**Technologies, Bioprocessing & Manufacturing**

### Conference Highlights

**Keynote Speakers Session**  
**Symposium on HIV vaccines**  
**Multiple track sessions**  
**Participation from pharma, vaccines, biotech small to medium cap companies**  
**Networking & Partnering opportunities**  
**Key issues in Q&A panel sessions**  
**Excellent line-up of renowned speakers from govt, academia, industry and non-profit organizations**  
**Poster presentations**


**Organizer**



**Bronze Sponsor**



**Exhibitor**



**Venue:**

**Sheraton Reston Hotel**

11810 Sunrise Valley Dr, Reston

VA 20191

USA

Ph: +1 703-620-9000

**Day-1 November 13, 2017**

09:00-16:00

**Keynote Speakers**

**Title:** *Translation of cancer vaccines from mice to human clinical trials*

**Jay A. Berzofsky**, National Cancer Institute, USA

**Title:**

**Nancy Sullivan**, Vaccine Research Center NIH/NIAID, USA

**Title:** *Vaccine design to safely induce protective immunity of long duration*

**Roy Curtiss III**, University of Florida, USA

**Title:**

**Peter L. Nara**, Biological Mimetics, Inc., USA

**Title:**

**Manuel Elkin Patarroyo M**, FIDIC, Colombia

**Title:**

**Stephen L. Hoffman**, Sanaria Inc., USA

**Title:** *A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition*

**Michael G. Hanna**, Vaccinogen, Inc., USA

**Title:**

**Odile Leroy**, European Vaccine Initiative, Germany

**Title:** *Successfully activating positive behaviors of the stakeholders involved in vaccine purchasing and usage through technological advances*

**Pierre A. MORGON**, MRGN Advisors, Switzerland

**Title:**

**David B. Weiner**, The Wistar Institute Vaccine Center, USA

16:00-18:00

***"Special Session on Vaccine Regulation"***

**Title:** *Challenges for registration of vaccines at global level*

**Nora Dellepiane**, Serum Institute of India Pvt. Ltd

**Title:**

**Kelsy Hofman**, CBER/FDA

**Title:**

**Bartholomew Dicky Akanmori**, WHO/Afro

**Day-2 November 14, 2017**

**Symposium Title: The long road to an HIV vaccine**

08:00-10:30 **Co-chairs** : Richard Wyatt & Susan Zolla-Pazner

**Keynote Speakers**

08:00-08:30 **Title:**

**Susan Zolla-Pasner**, Langone Medical Center , New York University, USA

08:30-09:00 **Title:**

**Hanneke Schuitemaker**, Janssen Vaccines, The Netherlands

09:00-09:30 **Title:**

**Louis Picker**, Oregon Health & Science University, USA

09:30-10:00 **Title:**

**Neil S. Greenspan**, Case Western Reserve University, USA

10:00-10:30 **Title:**

**Marc Van Regenmortel**, Strasbourg University, France

Coffee Break 10:30-11:00

11:00-12:40 **Session-I Co-chairs** : Marjorie Robert-Guroff & Neil S. Greenspan

11:00-11:25 **Title:** *HIV Env trimer immunogen design and modification to elicit neutralizing antibodies*

**Richard Wyatt**, Scripps Institute in La Jolla, CA USA

11:25-11:50 **Title:**

**Ruth Ruprecht**, Texas Biomedical Research Institute, USA

11:50-12:15 **Title:** *Fundamental challenges to the development of an HIV vaccine*

**Adan Rios**, University of Texas Medical School in Houston, USA

12:15-12:40 **Title:**

**Caroline T Tiemessen**, National Institute for Communicable Diseases South Africa

Lunch 12:40-13:40

13:40-15:20 **Session-II Co-chairs** : Ruth Ruprecht & Jose Esparza

13:40-14:05 **Title:**

**Angus Dalgleish**, St George's, University of London

14:05-14:30 **Title:**

**Jose Esparza**, Venezuelan American virologist

14:30-14:55 **Title:**

**Barbara Ensoli**, Istituto Superiore di Sanità, Italy

14:55-15:20 **Title:**

**Jean Marie Andrieu**, Descartes University, Paris

Coffee Break 15:20-15:50

15:50-19:05 **Session-III Co-chairs : Hanneke Schuitemaker & Marc Van Regenmortel**

15:50-16:15 **Title:**

**Marjorie Robert-Guroff**, National Cancer Institute, USA

16:15-16:40 **Title: *The road to a pediatric HIV vaccine***

**Kristina De Paris**, UNC at Chapel Hill, USA

16:40-17:05 **Title: *HIV Env antibody can provide sterilizing immunity in the strictest sense***

**Klaus Überla**, University Hospital Erlangen, Virology Institute, Germany

17:05-17:30 **Title: *Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication. Underappreciated role of location and immunodominance in vaccination against chronic infection?***

**Peter Johannes Holst**, University of Copenhagen, Denmark

17:30-17:55 **Title: *Orally delivered mucosal vaccine targeting colorectal immunity protected SHIV transmission in macaques***

**Yongjun Sui**, National Cancer Institute, USA

17:55-18:20 **Title: *Stabilization of gp120 outer domain for HIV vaccine immunogen design***

**Shi-hua Xiang**, University of Nebraska-Lincoln, Nebraska Center for Virology, USA

18:20-18:45 **Title: *Improving antibody response to targeted epitopes of HIV envelope by immune complex vaccines***

**Catarina E. Hioe**, Mount Sinai School of Medicine, USA

18:45-19:05 **Title: *A HIV vaccine based on MTVV prime Adv boost controlled viral reservoir and conferred long-term protection from SIVmac239 infection***

**Ling Chen**, Guangzhou Medical University, China

## Day-2 November 14, 2017

08:00-18:00

### Cancer Vaccines

**Session Chair: Michael G. Hanna**, Vaccinogen, Inc., USA

**Title: *Targeting tumor associated carbohydrate antigens for cancer therapy***

**Thomas Kieber-Emmons**, University of Arkansas for Medical Sciences, USA

**Title: *Nano-vaccine platform technology for personalized cancer vaccination***

**James J. Moon**, University of Michigan, USA

**Title:** *Tumor liberated protein (TLP) as potential vaccine for lung cancer patients*

**Giulio Tarro**, Fondazione de Beaumont Bonelli per le ricerche sul cancro, Italy

**Title:** *Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity*

**Jasmin Leshem**, National Cancer Institute, USA

**Title:** *Analyses of data on pathogen-specific vaccines: Weakening or Promoting Immunity?*

**Mahin Khatami**, National Cancer Institute (retired), USA

**Title:** *Synthetic immunogens drive potent antigen specific anti-tumor immune responses*

**Bernadette Ferraro**, Inovio Pharmaceuticals, USA

*Curative efficacy of therapeutic mucosal HPV E6/E7 peptide vaccination combined with checkpoint modulation in preclinical mouse models of HPV+ genital and oral cancers*

**Jagannadha Sastry**, MD Anderson Cancer Center, USA

**Title:** *Enhancing the therapeutic efficacy of mucosal HPV E6/E7 peptide vaccination with checkpoint modulation in preclinical mouse models of HPV+ oral cancers*

**Stephanie Dorta-Estremera**, MD Anderson Cancer Center, USA

**Title:** *Changing the tumor microenvironment of PDAC by novel immune-chemotherapeutic approaches*

**Benson C. Selvanesan**, Albert Einstein College of Medicine

**Title:** *Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins*

**Nicolas Çuburu**, National Cancer Institute, USA

**Title:** *Cell immunogene therapy of cancers using anti - gene anti IGF-I vaccines*

**Jerzy Trojan**, UNAB University, Colombia

## Veterinary Vaccines

### Session Chair:

**Title:** *Veterinary vaccine research in support of biodefense and the threat of biological threat agents*

**Cyril Gerard Gay**, USDA/ARS, USA

**Title:** *Characterization and cross-protection evaluation of M949\_1603 gene deletion *Riemerella anatipestifer* mutant RA-M1*

**Shengqing YU**, Shanghai Veterinary Research Institute, China

**Title:** *Immune responses to *Mycobacterium bovis* in naturally infected ruminants*

**Gordon Harkiss**, MV Diagnostics Ltd, UK

**Title:** Novel universal nanoparticle vaccines for bird flu and coronavirus infections in birds  
**Jianping Li**, University of Connecticut, USA

**Title:** *Recombinant porcine reproductive and respiratory syndrome virus strain P129 expressing CSFV E2 glycoprotein enhanced pathogenesis of CSFV in pigs*  
**Lihua Wang**, Kansas State University, USA

**Title:** *Development of a one-dose classical swine fever sub-unit vaccine*  
**Rachel Madera**, Kansas State University, USA

**Title:** *Combination adjuvants in subunit veterinary vaccines*  
**Yulia Burakova**, Kansas State University, USA

08:00-17:00

### Infectious & Non-Infectious Diseases

**Session Chair:** **Marcelo B. Sztein**, University of Maryland, USA

**Title:** *Correlates of protection from S. Typhi infection in humans: Recent advances*  
**Marcelo B. Sztein**, University of Maryland, USA

**Title:** *Responding to the threat of emergent infectious diseases*  
**Klaus Schwamborn**, Valneva, France

**Title:** *T cell-mediated immune responses induced by the oral live-attenuated Shigella vaccine candidate CVD 1208S in humans*  
**Franklin R. Toapanta**, University of Maryland, USA

**Title:** *Initial and long-term stability study of Pfs230-EPA conjugates adjuvanted with Alhydrogel®*  
**Daming Zhu**, National Institute of Health, USA

**Title:** *Herpes Simplex Virus (HSV) gD-2 Vaccine Elicits High Titer FcR Activating Antibodies and Prevents Primary Infection and Latency in Multiple Small Animal Models*  
**Betsy Herold**, Albert Einstein College of Medicine, USA

**Title:** *A broad-spectrum anti-endotoxin vaccine for the prevention and treatment of Gram-negative bacterial infections*  
**Alan S Cross**, University of Maryland School of Medicine, USA

**Title:** *Development of novel and safe single-dose vaccines; preclinical efficacy data for zika, ebola and lassa fever*  
**Farshad Guirakhoo**, GeoVax Labs, USA

**Title:** *Immune frailty: role of viral infection and impact on vaccination in the elderly*  
**Graham Pawelec**, University of Tuebingen, Germany

**Title:** *Novel epitopes identified from Mycobacterium tuberculosis antigen Rv2629 could induce cytotoxic T lymphocyte response*

**Bai Xuejuan**, the 309th Hospital of Chinese PLA, China

**Title:** *Seroprevalence of measles among children aged 5-10 years in Chandigarh, North India*

**Madhu Gupta**, Post Graduate Institute of Medical Education and Research, India

**Title:** *Immunization with recombinant DIM-1 protein of Brugia malayi induce T and B cell immunogenicity and protect mice against B. malayi infection*

**Vikas Kushwaha**, Panjab University, India

**Day-3 November 15, 2017**

08:00-17:00

**Biodenfense Vaccines**

**Vaccines Against Respiratory Pathogens**

**Session Chair:**

**Title:** *Deconvolution of neutralizing antibody response induced by a trivalent parainfluenza-vectored ebolavirus vaccine*

**J. Brian Kimble**, University of Texas Medical Branch, USA

**Title:** *Development of a lipopolysaccharide targeted mimotope vaccine against Q fever*

**Guoquan Zhang**, University of Missouri-Columbia, USA

**Title:** *Comparative analysis of the antibody threshold of protection for the licensed biothrax anthrax vaccine and other novel anthrax vaccine candidates*

**Mario H. Skiadopoulos**, Emergent BioSolutions Inc., USA

**Title:** *Conjugate rPA-PGA anthrax vaccine induces protective antibodies*

**Christine Ferragine**, Biologics Resources LLC, USA

**Title:** *Use of an outbred mouse model for Francisella tularensis vaccine development and testing*

**Raju Sunagar**, Albany Medical College, USA

**Title:** *Optimization of Fc receptor targeting for improved mucosal vaccine delivery*

**Sudeep Kumar**, Albany Medical College, USA

**Title:** *Vaccine elicited broadly neutralizing antibodies against New World hemorrhagic fever arenaviruses*

**Jonathan Abraham**, Harvard Medical School, USA

**Title:** *Enhanced protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein*

**Fu Shi Quan**, Kyung Hee University School of Medicine, Korea

**Title:** *The Importance of RSV F protein conformation in stimulation of neutralizing antibodies in mice previously infected with RSV*

**Trudy G Morrison**, University of Massachusetts Medical School, USA

**Title:** *Pre-vaccination baseline levels of F-specific IgG and palivizumab epitope-specific antibodies predicted vaccine efficacy and failure*

**Mark T. Esser**, MedImmune, USA

**Title:** *Reshaping acellular pertussis vaccine-induced immune responses by the novel adjuvant, BcFA*

**Purnima Dubey**, Wake Forest University, USA

**Title:** *Immunoglobulin response to the low polymorphic Pf113 antigen in children from Lastoursville, South-East of Gabon*

**Jean Bernard LEKANA-DOUKI**, Centre International de Recherches Médicales de Franceville, Gabon

**Title:** *Expression of edema factor gene in plants-a novel step in the generation of edible vaccine against anthrax*

**Prerna Chaudhary**, Jawaharlal Nehru University, India

08:00-17:00

**Influenza Vaccines/Virus & Passive vaccines  
New Vaccine Development**

**Session Chair:**

**Title:** *ADCC reporter bioassay and vaccine development*

**Mei Cong**, Promega Corporation, USA

**Title:** *Stability improvements to subunit and live attenuated influenza vaccines*

**Jessica A White**, PATH, USA

**Title:** *Heterotypic T cell responses to inactivated and live attenuated seasonal influenza vaccines*

**Jay Bream**, Johns Hopkins Bloomberg School of Public Health, USA

**Title:** *Repeat annual seasonal influenza vaccination: The benefit of a changing vaccine formulation*

**Ewan P. Plant**, Center for Biologics Evaluation and Research, US FDA

**Title:** *Toward developing antibody-drugs for prophylaxis of HTLV-I infection and onset of Adult T-cell Leukemia (ATL)*

**Yuetsu TANAKA**, University of the Ryukyus, USA

**Title:** *Fighting pathogens and toxins with human and human-like recombinant*

**Michael Hust**, Technische Universität Braunschweig, Germany



**Title:** *Systematic evaluation of self-assembling and self-adjuvanting lipopeptide vaccine candidates for the induction of protective immune responses*

**Rachel Stephenson**, The University of Queensland, USA

**Title:** *Development of vaccines using Sendai virus vectors*

**Tetsuro Matano**, National Institute of Infectious Diseases, Japan

**Title:** *Recombinant BCG expressing SOCS1 antagonist as a novel BCG vaccine*

**Yasuhiro Yasutomi**, National Institutes of Biomedical Innovation, Japan

**Title:** *Antigen display and therapeutic potential of a buoyant VLP-like nanoparticle*

**Shiladitya DasSarma**, University of Maryland School of Medicine, USA

**Title:** *Age to end dreadful diseases (HIV, Malaria, TB, cancer and more): A theory of Intact or Protected Complement (IPC) immunity*

**Tom H. Jin**, IDT Biologika, USA

**Title:** *Characterization of significant molecular determinants of virulence of Enterovirus 71 sub-genotype B4 in Rhabdomyosarcoma cells*

**Isabel Yee**, Sunway University, Malaysia

**Title:** *Elimination of immunodominant B cells drives the germinal center reaction toward subdominant epitopes: A potential vaccination strategy to target broadly neutralizing epitopes*

**Murillo Silva**, Northeastern University, USA

08:00-17:00

**Therapeutic Vaccination & Clinical Trials & DNA Vaccines  
Technologies, Bioprocessing & Manufacturing & Vaccine Regulation**

**Session Chair:**

**Title:** *Cytolytic DNA vaccine to induce antigen cross-presentation by dendritic cells and liver tissue resident memory CD8+ T cells*

**Danushka Kumara Wijesundara**, The University of Adelaide, Australia

**Title:** *APC-targeting of antigen for increased efficacy of DNA vaccination*

**Gunnveig Grodeland**, University of Oslo, Norway

**Title:** *Resident humoral response elicited by repeatedly same site inoculations inhibits systemic immunity of gene based vaccines*

**Yanmin Wan**, University of Nebraska-Lincoln, USA

**Title:** *High therapeutic efficacy of a new cancer vaccine against the tumor associated antigen survivin*

**Ahmed Bouzidi**, Vaxeal Group, Switzerland

**Title:** *The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus*

**J. Patricia Dhar**, Wayne State University School of Medicine, USA

**Title:** *Therapeutic vaccine against primate papillomavirus infections of the cervix*

**Emeline Ragonnaud**, University of Copenhagen, USA

**Title:** *Pivotal role of cellular necrosis in residual cytotoxicity of a recombinant vaccine against Clostridium Difficile*

**Laura Hong**, Vaccine Bioprocess & Bioanalytical Research, USA

**Title:** *Overcoming bioprocess research and development hurdles to advance an LVV candidate for human cytomegalovirus*

**Matthew Woodling**, Merck & Co., Inc., USA

**Title:** *Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis*

**Yan Liang**, the 309th Hospital of Chinese PLA

**Title:** *Formulation approaches to vaccine development*

**S. Fernando Ausar**, Sanofi Pasteur, Canada

**Title:** *Imaging of germinal center immune dynamics: Applications in vaccine development*

**Constantinos Petrovas**, Vaccine Research Center, NIAID, NIH, USA

**Title:** *Process development of a glycoconjugate vaccine*

**Tracy Scott**, Pfizer, Inc., USA

### **Speaker Slots Available**

#### **Reserve your slot**

[https://www.unitedscientificgroup.com/conferences/vaccines/registration\\_form](https://www.unitedscientificgroup.com/conferences/vaccines/registration_form)

#### **Submit your abstract**

[https://www.unitedscientificgroup.com/conferences/vaccines/abstract\\_submission](https://www.unitedscientificgroup.com/conferences/vaccines/abstract_submission)

**Note:** *This is tentative program subject to change*